Homogeneous preparations of IL-31

• US 20060228329A1
• Filed: 01/30/2006
• Published: 10/12/2006
• Est. Priority Date: 01/28/2005
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Chan, Chung-leung, Bukowski, Thomas R., Brady, Lowell J.
• Application Number:
  US11/344,451
• Publication Number:
  US 20060228329A1
• Time in Patent Office: Days
• US Class Current: 424/85.100
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/54 Interleukins [IL]
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30.

2. An expression vector comprising the following operably linked elements:

a transcription promoter;

a DNA segment encoding a polypeptide of claim 1;

and

a transcription terminator.

3. A cultured cell into which has been introduced an expression vector of claim 2, wherein the cell expresses the polypeptide encoded by the DNA segment.

4. The cultured cell according to claim 3, wherein the cultured cell is a prokaryotic cell.

5. The cultured cell according to claim 4, wherein the cell is a gram negative cell.

6. The cultured cell according to claim 5, wherein the cell is E. coli.

7. The cultured cell according to claim 6, wherein the E. coli cell is E. coli strain W3110.

8. A process for producing a polypeptide comprising:

culturing a cell into which has been introduced an expression vector of claim 2, wherein the cell expresses the polypeptide encoded by the DNA segment; and

recovering the expressed polypeptide.

9. An antibody or antibody fragment that specifically binds to a polypeptide of claim 1.

10. The antibody of claim 9, wherein the antibody is selected from the group consisting of a polyclonal antibody, a murine monoclonal antibody, a humanized antibody derived from a murine monoclonal antibody, an antibody fragment, neutralizing antibody, and a human monoclonal antibody.

11. The antibody fragment of claim 9, wherein the antibody fragment is selected from the group consisting of F(ab′

), F(ab), Fab′

, Fab, Fv, scFv, and minimal recognition unit.

12. An anti-idiotype antibody comprising an anti-idiotype antibody that specifically binds to the antibody of claim 9.

16. The polypeptide according to claim 1, wherin the polypeptide is proinflammatory.

17. The polypeptide according to claim 1, wherein the amino acid is SEQ ID NOs:

14, 15, 16, 17, 18 or 19.

18. The polypeptide according to claim 1, wherein the amino acid is SEQ ID NOs:

21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.

13. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:

4, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30.

14. A formulation comprising:

an isolated polypeptide selected from the group consisting of SEQ ID NOs;

4, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30; and

a pharmaceutically acceptable vehicle.

15. A kit comprising the formulation of claim 14.

19. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:

14, 15, 16, 17, 18 or 19.

20. An isolated polypeptide comprising the amino acid sequence from residue 2 to residue 133 of SEQ ID NO:

23.